Search Results

Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and evolving practices within the field of respiratory and pulmonary medicine. We begin with a compelling […]

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are the dominant cause of the worsening and high mortality of chronic obstructive pulmonary disease (COPD), and are associated with higher healthcare costs as part of COPD management. AECOPD is characterized by worsening respiratory symptoms, quality of life, respiratory function and gas exchange.1 It represents a challenge in […]

Chronic cough is a cough that lasts 8 weeks or longer and is not due to serious underlying conditions. It is a common problem in primary care, accounting for up to 40% of referrals to pulmonologists.1 Common causes include rhinosinusitis, cough-variant asthma, eosinophilic bronchitis, smoking, certain medications (including angiotensin-converting enzyme inhibitors) and gastroesophageal reflux.2 Once […]

The definition of chronic obstructive pulmonary disease (COPD) has recently been reformulated better to encompass the heterogeneous nature of this lung condition.1 The new definition is broader, includes risk factors other than smoking, and aims to improve the diagnosis, management and clinical trials of a disorder with high morbidity and mortality rates.1 In this expert interview, […]

The ENHANCE-1 and ENHANCE-2 trials investigated the efficacy and safety of ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of patients with COPD. touchRESPIRATORY were delighted to speak with Prof. Antonio Anzueto (South Texas Veterans Healthcare System, University of Texas Health, San Antonio, TX, USA) around the aims, design, inclusion criteria and finding […]

Ensifentrine, is a dual phosphodiesterase 3 and 4 inhibitor recently investigated in the phase 3 ENHANCE trials for the treatment of COPD. touchRESPIRATORY were delighted to speak with Prof. Antonio Anzueto (South Texas Veterans Healthcare System, University of Texas Health, San Antonio, TX, USA) around the bronchodilators already available for the treatment of COPD, the […]

touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]

There is a genuine interest on the part of researchers and the pharmaceutical industry in developing so-called ‘bifunctional’ drugs – that is, single molecules with two different primary pharmacological actions.1,2 In this context, single molecules that are capable of simultaneously inducing bronchodilation and anti-inflammatory activity are a highly intriguing possibility for treating a variety of obstructive […]